For clarifying whether the subcellular distribution of Kaiso in K562 cells correlates with BCR/ABL activity, connecting Kaiso directly to CML, we performed inhibition of BCR/ABL by imatinib after 16 h of treatment. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.